BioBehavioral Diagnostics Company (BioBDx) develops diagnostic systems that aid clinicians in the objective assessment of behavioral and neurobiological disorders. The company’s lead product, the Quotient™ ADHD System1, is the first FDA cleared2 test that offers medical professionals an office-based capability to conduct rapid, precise and objective patient assessments that inform and guide a medical professional to an ADHD diagnosis. Using the Quotient™ ADHD System, healthcare professionals are able to precisely measure the three core symptoms of ADHD (inattention, hyperactivity and impulsivity), and establish a baseline to inform the course of treatment.
BioBDx is leading the way towards a transformation of behavioral and neurobiological medicine, in which the diagnosis and treatment of difficult-to-establish neurological and psychiatric conditions can be made rapidly, objectively, and quantifiably. The ultimate beneficiaries of objective diagnosis and treatment will be the patients, who will receive more timely, appropriate and effective care.
1. The Quotient™ ADHD System was formerly known as the MMAT/ADHD™ System.
2. FDA clearance of this product does not in any way denote FDA approval of the device.
